Ipsen to co-develop and commercialise Active Biotech's Phase III prostate cancer drug
This article was originally published in Scrip
Executive Summary
The Swedish biotech firm, Active Biotech, has entered into a partnership to co-develop and commercialise its investigational prostate cancer compound, ABR-215050 (tasquinimod), with Ipsen.